MX370492B - 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3, 2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa. - Google Patents

1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3, 2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa.

Info

Publication number
MX370492B
MX370492B MX2017007322A MX2017007322A MX370492B MX 370492 B MX370492 B MX 370492B MX 2017007322 A MX2017007322 A MX 2017007322A MX 2017007322 A MX2017007322 A MX 2017007322A MX 370492 B MX370492 B MX 370492B
Authority
MX
Mexico
Prior art keywords
thioxo
pyrrolo
pyrimidin
aminomethyl
tetrahydro
Prior art date
Application number
MX2017007322A
Other languages
English (en)
Other versions
MX2017007322A (es
Inventor
Bertil Inghardt Tord
Tomkinson Nicholas
Ming GAN Li-
Paul Stonehouse Jeffrey
Johannesson Petra
Jurva Ulrik
Michaëlsson Erik
Lindstedt-Alstermark Eva-Lotte
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2017007322A publication Critical patent/MX2017007322A/es
Publication of MX370492B publication Critical patent/MX370492B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se dan a conocer determinados compuestos de 1-[2-(aminometil)benci l]-2-tioxo-1,2,3,5-tetrahidro-4H-pirrolo[3,2-d]pirimidin-4-ona de fórmula (I), (ver Fórmula) y sales farmacéuticamente aceptables de los mismos, junto con composiciones que los contienen y su uso en terapia. Los compuestos son inhibidores de la enzima MPO y de este modo son particularmente útiles en el tratamiento o profilaxis de trastornos cardiovasculares tales como insuficiencia cardíaca y afecciones relacionadas con arteriopatía coronaria.
MX2017007322A 2014-12-01 2015-11-30 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3, 2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa. MX370492B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462085722P 2014-12-01 2014-12-01
US201562166808P 2015-05-27 2015-05-27
PCT/EP2015/077998 WO2016087338A1 (en) 2014-12-01 2015-11-30 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase

Publications (2)

Publication Number Publication Date
MX2017007322A MX2017007322A (es) 2018-02-19
MX370492B true MX370492B (es) 2019-12-16

Family

ID=54754631

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007322A MX370492B (es) 2014-12-01 2015-11-30 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3, 2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa.

Country Status (38)

Country Link
US (5) US9616063B2 (es)
EP (1) EP3227294B1 (es)
JP (1) JP6616417B2 (es)
KR (1) KR102543404B1 (es)
CN (1) CN107001374B (es)
AU (1) AU2015357290B2 (es)
BR (1) BR112017011124B1 (es)
CA (1) CA2968449C (es)
CL (1) CL2017001380A1 (es)
CO (1) CO2017006658A2 (es)
CY (1) CY1122587T1 (es)
DK (1) DK3227294T3 (es)
DO (1) DOP2017000129A (es)
EA (1) EA030805B1 (es)
ES (1) ES2751690T3 (es)
GT (1) GT201700114A (es)
HR (1) HRP20191744T1 (es)
HU (1) HUE045606T2 (es)
IL (1) IL252436B (es)
LT (1) LT3227294T (es)
ME (1) ME03568B (es)
MX (1) MX370492B (es)
MY (1) MY195816A (es)
NI (1) NI201700065A (es)
NZ (1) NZ732164A (es)
PE (1) PE20170914A1 (es)
PH (1) PH12017500977A1 (es)
PL (1) PL3227294T3 (es)
PT (1) PT3227294T (es)
RS (1) RS59375B1 (es)
SG (1) SG11201703961UA (es)
SI (1) SI3227294T1 (es)
SM (1) SMT201900572T1 (es)
SV (1) SV2017005451A (es)
TN (1) TN2017000208A1 (es)
TW (1) TWI681963B (es)
UY (1) UY36416A (es)
WO (1) WO2016087338A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
KR102705858B1 (ko) 2017-07-17 2024-09-10 아스트라제네카 아베 의약에서의 사용을 위한 mpo 억제제
CN112151111B (zh) * 2020-08-27 2022-10-11 上海大学 基于多元线性回归快速预测黄嘌呤衍生物抑制活性的qsar方法
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
AR130237A1 (es) 2022-08-18 2024-11-20 Astrazeneca Ab Inhibidores de mieloperoxidasa
US20240092787A1 (en) 2022-08-24 2024-03-21 Astrazeneca Ab Pharmaceutical process and intermediates
AU2023332020A1 (en) 2022-08-31 2025-04-17 Astrazeneca Ab Pharmaceutical formulation
CN120265633A (zh) * 2022-12-09 2025-07-04 深圳信立泰药业股份有限公司 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途
WO2024209075A1 (en) * 2023-04-06 2024-10-10 Astrazeneca Ab Method of treatment with mpo inhibitors
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
CN121378265A (zh) * 2025-10-30 2026-01-23 乐平市康鑫医药化工有限公司 一种吡唑类化合物及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
US20050130983A1 (en) * 2002-05-02 2005-06-16 Dae-Kee Kim Pyrrolopyrimidinone derivatives, process for preparation thereof, and method of using and composition comprising them
SE0302756D0 (sv) 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
GB0401269D0 (en) * 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
EP1838712B8 (en) * 2004-12-14 2011-10-12 AstraZeneca AB Pyrazolopyrimidine compounds as antitumor agents
JP2009533426A (ja) 2006-04-13 2009-09-17 アストラゼネカ・アクチエボラーグ チオキサンチン誘導体およびそれらのｍｐｏ阻害剤としての用途
TW200806667A (en) 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
EP2029603A1 (en) 2006-06-05 2009-03-04 Astra Zeneca AB Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
MD20140044A2 (ro) 2011-11-11 2014-08-31 Pfizer Inc. 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase

Also Published As

Publication number Publication date
EP3227294B1 (en) 2019-08-14
CA2968449C (en) 2023-02-28
JP2017535588A (ja) 2017-11-30
IL252436B (en) 2021-05-31
US12569489B2 (en) 2026-03-10
CN107001374B (zh) 2019-06-14
SI3227294T1 (sl) 2019-11-29
ME03568B (me) 2020-07-20
US9616063B2 (en) 2017-04-11
IL252436A0 (en) 2017-07-31
CA2968449A1 (en) 2016-06-09
TN2017000208A1 (en) 2018-10-19
KR20170088900A (ko) 2017-08-02
EP3227294A1 (en) 2017-10-11
HUE045606T2 (hu) 2020-01-28
PH12017500977A1 (en) 2017-11-27
UY36416A (es) 2016-06-01
TW201639846A (zh) 2016-11-16
US11975004B2 (en) 2024-05-07
BR112017011124B1 (pt) 2022-11-16
GT201700114A (es) 2019-08-12
SG11201703961UA (en) 2017-06-29
US20210228585A1 (en) 2021-07-29
RS59375B1 (sr) 2019-11-29
HK1245270A1 (en) 2018-08-24
EA201791021A1 (ru) 2017-11-30
AU2015357290A1 (en) 2017-06-15
EA030805B1 (ru) 2018-09-28
DK3227294T3 (da) 2019-10-21
MX2017007322A (es) 2018-02-19
PE20170914A1 (es) 2017-07-12
DOP2017000129A (es) 2017-09-15
US11000525B2 (en) 2021-05-11
WO2016087338A1 (en) 2016-06-09
PT3227294T (pt) 2019-10-28
SV2017005451A (es) 2017-10-12
PL3227294T3 (pl) 2020-04-30
US20190076432A1 (en) 2019-03-14
NI201700065A (es) 2018-01-04
US20240335446A1 (en) 2024-10-10
NZ732164A (en) 2018-02-23
AU2015357290B2 (en) 2018-03-29
SMT201900572T1 (it) 2019-11-13
US10016430B2 (en) 2018-07-10
CO2017006658A2 (es) 2017-10-20
ES2751690T3 (es) 2020-04-01
CY1122587T1 (el) 2021-01-27
CN107001374A (zh) 2017-08-01
BR112017011124A2 (pt) 2017-12-26
JP6616417B2 (ja) 2019-12-04
KR102543404B1 (ko) 2023-06-14
LT3227294T (lt) 2019-10-25
TWI681963B (zh) 2020-01-11
MY195816A (en) 2023-02-22
CL2017001380A1 (es) 2018-01-12
US20160152623A1 (en) 2016-06-02
HRP20191744T1 (hr) 2019-12-27
US20170173025A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
MX370492B (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3, 2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2018000119A1 (es) Compuestos pirazolo[1,5-a]piridina sustituidos como inhibidores de quinasa de ret.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
MX2015017865A (es) Compuestos de pirimidinodiona contra estados cardiacos.
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
UY37098A (es) Moduladores de ror-gamma
MX2018004892A (es) Compuestos de 2-piridazin-3(2h)-ona 2-aril sustituidas y 2-heteroaril sustituidas como inhibidores de las tirosina quinasas fgfr.
MX2017004129A (es) Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2- il)amino-benzoico como inhibidor de quinasa p38.
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
MX2020012520A (es) Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia.
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MX2015015738A (es) Derivados del bipirazol como inhibidores de janus cinasa (jak).
CL2012003178A1 (es) Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmaceuticamente aceptables, como inhibidores de pde10; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de parkinson, depresion, trastornos del humor y demencia.
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
AR081628A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
UY30267A1 (es) Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MX2016007410A (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
CL2020000944A1 (es) Compuestos bicíclicos y métodos de utilización de los mismos.
MX2018004664A (es) Antagonistas de ep4.
MX2017016347A (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.

Legal Events

Date Code Title Description
FG Grant or registration